Aumoltertinib is a third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and has achieved potent efficacy for advanced EGFR-mutated non-small cell lung cancer patients. Phase 2 non-randomized clinical trial was conducted at…
Category: Lung Cancer Drugs
Get an ideas about the lung cancer treatment drugs, here we provide only information about drugs not to advice them to take without proper doctor guideline. For information about lung cancer drugs browse.
Taletrectinib Received FDA Approval for ROS1-Positive NSCLC
Recently, FDA has granted approval to Taletrectinib for treatment of locally advanced or metastatic ROS1-positive non-small cell lung cancer in adults. Taletrectinib has demonstrated high response rates and was well tolerated among…
Tarlatamab Shows Improved Overall Survival Over Chemotherapy in SCLC
Tarlatamab received accelerated approval for treatment of patients with previously treated small-cell lung cancer. It meaningfully improved overall survival compared with Chemotherapy in SCLC patients that progressed on or after initial platinum-based…
Study: Tagrisso As Backbone Therapy for Lung Cancer
Lung cancer remains the leading cause of cancer-related deaths worldwide. It is broadly classified into small cell lung cancer and non-small cell lung cancer. The latter accounts for about 80% of the…
Metformin Appears To Fight Lung Cancer But Only In Overweight Patients
Metformin is a common drug prescribed for patients with Type 2 patients to lower their blood sugar. It is a FDA approved drug since 1995 and is used by about 20 million…
FDA Approves New Drug for Lung Cancer
Lung cancer is one of the leading causes behind cancer related deaths. Various studies and research works are going on to help lung cancer patients to get cure from this disease. Time-to-time,…
Tarlatamab for Small Cell Lung Cancer
Lung cancer is the second most form of cancers and remains the leading cause of cancer deaths. A variety of new treatments are helping to bring down the number of deaths from…
FDA Approves Optune Luna for Metastatic NSCLC
U.S. based FDA has approved Optune Lua for concurrent use with PD-1/PD-L1 inhibitors for treatment of patients with metastatic non-small cell lung cancer and whose disease has progressed on or after platinum-based…